Symbol="AKBA"
AssetType="Common Stock"
Name="Akebia Ther"
Description="Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts."
CIK="1517022"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="245 FIRST STREET, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="290004000"
EBITDA="-24141000"
PERatio="None"
PEGRatio="0"
BookValue="-0.077"
DividendPerShare="0"
DividendYield="0"
EPS="-0.4"
RevenuePerShareTTM="1.085"
ProfitMargin="-0.482"
OperatingMarginTTM="-0.308"
ReturnOnAssetsTTM="-0.0066"
ReturnOnEquityTTM="-9.58"
RevenueTTM="200647000"
GrossProfitTTM="141801000"
DilutedEPSTTM="-0.4"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.555"
AnalystTargetPrice="3.88"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="0.281"
PriceToBookRatio="4.117"
EVToRevenue="0.0443"
EVToEBITDA="-0.13"
Beta="0.77"
num_52WeekHigh="1.84"
num_52WeekLow="0.241"
num_50DayMovingAverage="1.255"
num_200DayMovingAverage="0.864"
SharesOutstanding="185928000"
DividendDate="None"
ExDividendDate="None"
symbol="AKBA"
open="1.53"
high="1.53"
low="1.38"
price="1.40"
volume="2547022.00"
latest_trading_day="2023-08-30"
previous_close="1.54"
change="-0.14"
change_percent="-9.0909%"
aroon_positive_momentum_days="77"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="77"
Volume_recent_avg="1885706"
Change_recent_avg="0.01"
Delta_recent_avg="0.12"
Variance_recent_avg="0.06"
Change_ratio_recent_avg="0.28"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="77"
Aroon_momentum_negative="23"
image_negative_thumbnail_id_1="1161"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0195.jpeg"
image_negative_thumbnail_id_2="1118"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0151.jpeg"
image_neutral_thumbnail_id_1="527"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0072.jpeg"
image_neutral_thumbnail_id_2="552"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0047.jpeg"
image_positive_thumbnail_id_1="954"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0116.jpeg"
image_positive_thumbnail_id_2="668"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0040.jpeg"
image_professor_thumbnail_id_1="1188"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0022.jpeg"
image_professor_thumbnail_id_2="1190"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0024.jpeg"
